Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
3
60%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Not yet recruiting2
Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)

Trials by Status

not_yet_recruiting240%
recruiting120%
completed240%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_3

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380
completedphase_2

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT05649722
not_yet_recruitingphase_3

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981
not_yet_recruitingphase_3

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07234032
completedphase_1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

NCT06091579

Clinical Trials (5)

Showing 5 of 5 trials
NCT07179380Phase 3

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Recruiting
NCT05649722Phase 2

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Completed
NCT07481981Phase 3

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Not Yet Recruiting
NCT07234032Phase 3

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Not Yet Recruiting
NCT06091579Phase 1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5